Browse by author
Lookup NU author(s): Professor Andrew Pearson, Professor Roderick Skinner
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2021 Wiley Periodicals LLCWhile considerable efforts and progress in our understanding of the long-term toxicities of surgery, radiation and chemotherapy in children with cancer have been made over the last 5 decades, there continues to be a wide gap in our knowledge of the long-term health impact of most novel targeted and immunotherapy agents. To address this gap, ACCELERATE, a multi-stakeholder collaboration of clinical and translational academics, regulators from the EMA and FDA, patient/family advocates and members spanning small biotechnology through to large pharmaceutical companies have initiated the development of an international long-term follow-up data registry to collect this important information prospectively. Providing critical safety data on the long-term use of these approved and investigational therapies in children will support the regulatory requirements and labeling information. It will also provide the necessary insight to help guide physicians and families on the appropriateness of a targeted or immune therapy for their child and inform survivorship planning.
Author(s): Kieran MW, Caron H, Winther JF, Henderson TO, Haupt R, Hjorth L, Hudson MM, Kremer LCM, van der Pal HJ, Pearson ADJ, Pereira L, Reaman G, Skinner R, Vassal G, Weiner SL, Horton Taylor D
Publication type: Note
Publication status: Published
Journal: Pediatric Blood and Cancer
Year: 2021
Volume: 68
Issue: 7
Print publication date: 01/07/2021
Online publication date: 16/04/2021
Acceptance date: 18/03/2021
ISSN (print): 1545-5009
ISSN (electronic): 1545-5017
Publisher: John Wiley and Sons Inc
URL: https://doi.org/10.1002/pbc.29047
DOI: 10.1002/pbc.29047
